IRIX

IRIDEX Corporation

IRIX, USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

https://www.iridex.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IRIX
stock
IRIX

Iridex Corporation Announces Positive Findings on MicroPulse Technology for Glaucoma Retreatment in Independent Study Quiver Quantitative

Read more →
IRIX
stock
IRIX

Iridex Corporation Announces Publication of Study on Thermal Dynamics of Laser Treatments for Glaucoma Quiver Quantitative

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.35

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-33.60 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.55 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-9.38 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

5.06

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 20.01% of the total shares of IRIDEX Corporation

1.

PARAGON Assoc & PARAGON Assoc II JV

(5.885%)

since

2025/06/30

2.

Vanguard Group Inc

(3.4475%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.3649%)

since

2025/07/31

4.

Renaissance Technologies Corp

(2.229%)

since

2025/06/30

5.

AMH Equity Ltd

(1.1182%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.7755%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6635%)

since

2025/07/31

8.

Fidelity Extended Market Index

(0.3978%)

since

2025/07/31

9.

Apexium Financial, LP

(0.3866%)

since

2025/06/30

10.

Thompson Davis & Co Inc

(0.3338%)

since

2025/06/30

11.

Perkins Capital Management Inc

(0.2784%)

since

2025/06/30

12.

State Street Corp

(0.2632%)

since

2025/06/30

13.

Susquehanna International Group, LLP

(0.2274%)

since

2025/06/30

14.

Bank of New York Mellon Corp

(0.1856%)

since

2025/06/30

15.

Citadel Advisors Llc

(0.1834%)

since

2025/06/30

16.

XTX Topco Ltd

(0.1484%)

since

2025/06/30

17.

Northern Trust Corp

(0.1466%)

since

2025/06/30

18.

BlackRock Inc

(0.1192%)

since

2025/06/30

19.

Fidelity Series Total Market Index

(0.0993%)

since

2025/07/31

20.

Fidelity Nasdaq Composite Index

(0.087%)

since

2025/07/31

21.

Fidelity Total Market Index

(0.0852%)

since

2025/07/31

22.

Spartan Extended Market Index Pool F

(0.0729%)

since

2025/07/31

23.

NT Ext Equity Mkt Idx Fd - NL

(0.0638%)

since

2025/06/30

24.

HighTower Advisors, LLC

(0.0589%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - L

(0.0552%)

since

2025/06/30

26.

Northern Trust Extended Eq Market Idx

(0.0552%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0495%)

since

2025/06/30

28.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0418%)

since

2024/12/31

29.

Spartan Total Market Index Pool G

(0.0328%)

since

2025/07/31

30.

Tower Research Capital LLC

(0.0322%)

since

2025/06/30

31.

Vanguard U.S. Eq Idx £ Acc

(0.0233%)

since

2025/07/31

32.

NT Quality Small Cap Core

(0.0212%)

since

2025/06/30

33.

NT Quality SCC US Fund - L

(0.0212%)

since

2025/06/30

34.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0156%)

since

2025/06/30

35.

State St US Extended Mkt Indx NL Cl C

(0.0139%)

since

2025/08/31

36.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0131%)

since

2024/12/31

37.

State St US Ttl Mkt Indx NL Cl A

(0.0088%)

since

2025/08/31

38.

Group One Trading, LP

(0.0065%)

since

2025/06/30

39.

SIMPLEX TRADING, LLC

(0.0007%)

since

2025/03/31

40.

Bank of America Corp

(0.0007%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0925

EPS Estimate

-0.06

EPS Difference

-0.0325

Surprise Percent

-54.1667%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.